Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 α-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer

Purpose Actinium-225-labeled prostate-specific membrane antigen ([ 225 Ac]Ac-PSMA-617) is safe and effective in the treatment of metastatic castration-resistant prostate cancer (mCRPC). No study has specifically assessed its safety in patients with extensive skeletal metastases of mCRPC. We aimed to...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of nuclear medicine and molecular imaging 2022-08, Vol.49 (10), p.3581-3592
Hauptverfasser:	Lawal, Ismaheel O., Morgenstern, Alfred, Vorster, Mariza, Knoesen, Otto, Mahapane, Johncy, Hlongwa, Khanyisile N., Maserumule, Letjie C., Ndlovu, Honest, Reed, Janet D., Popoola, Gbenga O., Mokoala, Kgomotso M. G., Mdlophane, Amanda, Bruchertseifer, Frank, Sathekge, Mike M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Actinium Anemia Anticancer properties Antigens Bone marrow Cardiology Castration Hemoglobin Imaging Leukocytes Leukopenia Medicine Medicine & Public Health Metastases Metastasis Nuclear Medicine Oncology Oncology – Genitourinary Original Article Orthopedics Parameters Patients Population studies Positron emission tomography Prostate cancer Prostate-specific antigen Radiology Regression analysis Renal function Risk analysis Risk factors Survival Therapy Thrombocytopenia Toxicity Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!